Male breast cancer during finasteride therapy.
D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D018567:Breast Neoplasms, Male / Q000139:chemically induced*; D044584:Carcinoma, Ductal / Q000139:chemically induced*; D017292:Doxazosin / Q000008:administration & dosage / Q000009:adverse effects; D004348:Drug Labeling / Q000592:standards; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D018120:Finasteride / Q000008:administration & dosage / Q000009:adverse effects*; D006177:Gynecomastia / Q000139:chemically induced; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D014481:United States
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D004791:Enzyme Inhibitors; D018120:Finasteride; D017292:Doxazosin